- $479.14m
- $811.49m
- $1.10bn
- 90
- 71
- 62
- 87
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 11.86 | ||
| PEG Ratio (f) | 0.28 | ||
| EPS Growth (f) | 73.05% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.17 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 9.08 | ||
| Price to Sales | 0.43 | ||
| EV to EBITDA | 9.94 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.46% | ||
| Return on Equity | 0.99% | ||
| Operating Margin | 3.36% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 709.43 | 780.05 | 932.53 | 921.51 | 1,101.96 | 1,149.23 | 1,217.81 | 15.83% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | +123.17 | +21.66 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PetIQ, Inc. is a pet medication and wellness company, which provides veterinary products and services. The Company operates through two segments: Products and Services. Products segment manufactures and distributes pet medication and health and wellness products to major United States retail and e-commerce channels through more than 60,000 points of distribution. It is focused its offerings on value-branded products, and third-party branded products for dogs and cats, including pet Rx medications, OTC medications, and wellness products. Services segment provides a comprehensive suite of services at approximately 2,600 community clinic locations and wellness centers hosted at retailers across 39 states. The segment’s services include diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene and wellness checks. The Rx pet medications products include flea and tick control, heartworm preventatives, arthritis, thyroid, and other specialty medications.
Directors
- McCord Christensen CHM (48)
- Susan Sholtis PRE (54)
- Zvi Glasman CFO (56)
- Michael Smith EVP (43)
- R. Herrman GCN (53)
- Mark First LED (56)
- Larry Bird IND (66)
- Scott Huff IND (49)
- Kimberly Lefko IND (48)
- Sheryl Oloughlin IND (54)
- Kenneth Walker IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 29th, 2016
- Public Since
- July 21st, 2017
- No. of Shareholders
- 16
- No. of Employees
- 1,933
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 29,431,318
- Address
- Petiq Llc, 230 E. Riverside Dr., EAGLE, 83616
- Web
- https://petiq.com/
- Phone
- +1 2089398900
- Auditors
- KPMG LLP
Upcoming Events for PETQ
PetIQ Inc Annual Shareholders Meeting
PetIQ Inc Annual Shareholders Meeting
Q2 2024 PetIQ Inc Earnings Release
Similar to PETQ
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
Anika Therapeutics
NASDAQ Global Select Market
FAQ
What is the PetIQ share price?
As of Today at 19:16 UTC, shares in PetIQ are trading at $16.28. This share price information is delayed by 15 minutes.
How has the PetIQ share price performed this year?
Shares in PetIQ last closed at $16.28 and the price had moved by +38.2% over the past 365 days. In terms of relative price strength the PetIQ share price has outperformed the S&P500 Index by +15% over the past year.
What are the analyst and broker recommendations for PetIQ?
The overall consensus recommendation for PetIQ is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the PetIQ dividend yield?
PetIQ does not currently pay a dividend.
Does PetIQ pay a dividend?
PetIQ does not currently pay a dividend.
When does PetIQ next pay dividends?
PetIQ does not currently pay a dividend.
How do I buy PetIQ shares?
To buy shares in PetIQ you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of PetIQ?
As of the previous close price of $16.28, shares in PetIQ had a market capitalisation of $479.14m.
Where are PetIQ shares listed?
Here are the trading details for PetIQ:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PETQ
What kind of share is PetIQ?
Based on an overall assessment of its quality, value and momentum PetIQ is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a PetIQ share price forecast for 2024?
The analyst consensus target price for shares in PetIQ is $29.00. That is 78.13% above the last closing price of $16.28.
Analysts covering PetIQ currently have a consensus Earnings Per Share (EPS) forecast of $1.29 for the next financial year.
What is the trend in the PetIQ share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PetIQ. Over the past six months, its share price has underperformed the S&P500 Index by -27.41%.
As of the last closing price of $16.28, shares in PetIQ were trading -10.87% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the PetIQ PE Ratio?
The PetIQ PE ratio based on its reported earnings over the past 12 months is 11.86. The shares last closed at $16.28.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of PetIQ?
PetIQ's management team is headed by:
- McCord Christensen - CHM
- Susan Sholtis - PRE
- Zvi Glasman - CFO
- Michael Smith - EVP
- R. Herrman - GCN
- Mark First - LED
- Larry Bird - IND
- Scott Huff - IND
- Kimberly Lefko - IND
- Sheryl Oloughlin - IND
- Kenneth Walker - IND